A high intake of brassica vegetables may be associated with a decreased chronic disease risk. Health promoting effects of Brassicaceae have been partly attributed to glucosinolates and in particular to their hydrolyzation products including isothiocyanates. In vitro and in vivo studies suggest a chemopreventive activity of isothiocyanates through the redox-sensitive transcription factor Nrf2. Furthermore, studies in cultured cells, in laboratory rodents, and also in humans support an anti-inflammatory effect of brassica-derived phytochemicals. However, the underlying mechanisms of how these compounds mediate their health promoting effects are yet not fully understood. Recent findings suggest that brassica-derived compounds are regulators of epigenetic mechanisms. It has been shown that isothiocyanates may inhibit histone deacetylase transferases and DNA-methyltransferases in cultured cells. Only a few papers have dealt with the effect of brassica-derived compounds on epigenetic mechanisms in laboratory animals, whereas data in humans are currently lacking. The present review aims to summarize the current knowledge regarding the biological activities of brassica-derived phytochemicals regarding chemopreventive, anti-inflammatory, and epigenetic pathways. 1. Introduction Epidemiological studies link a high intake of brassica vegetables with a lower incidence for different kinds of cancers [1–3]. Health promoting effects of brassica vegetables have been attributed to glucosinolates, sulfur containing compounds almost exclusively present in plants of the family Brassicaceae. However, these chemopreventive effects are not mediated by glucosinolates per se but mainly through isothiocyanates, one of the major hydrolysis products resulting from myrosinase cleavage [4–9]. Myrosinase is a thioglucohydrolase located apart from glucosinolates in so-called myrosin cells. Upon plant cell disruption enzyme and glucosinolate get in contact and hydrolization is initiated. Based on reaction conditions (e.g., pH, temperature) either isothiocyanates, thiocyanates, or nitriles are formed (Figure 1) [10, 11]. Figure 1: Myrosinase-mediated hydrolysis of glucosinolates with main break-down products (modified according to [ 114]). Several in vitro and in vivo studies suggest that brassica derived phytochemicals may counteract inflammatory pathways and exhibit chemopreventive activity. Furthermore, impact of glucosinolates and/or their corresponding hydrolyzation products on epigenetic mechanisms including DNA-methylation, histone modification, and microRNAs has been recently
References
[1]
D. T. H. Verhoeven, R. A. Goldbohm, G. Van Poppel, H. Verhagen, and P. A. Van Den Brandt, “Epidemiological studies on Brassica vegetables and cancer risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 5, no. 9, pp. 733–748, 1996.
[2]
D. T. H. Verhoeven, H. Verhagen, R. A. Goldbohm, P. A. Van Den Brandt, and G. Van Poppel, “A review of mechanisms underlying anticarcinogenicity by brassica vegetables,” Chemico-Biological Interactions, vol. 103, no. 2, pp. 79–129, 1997.
[3]
L. E. Voorrips, R. A. Goldbohm, G. Van Poppel, F. Sturmans, R. J. J. Hermus, and P. A. Van Den Brandt, “Vegetable and fruit consumption and risks of colon and rectal cancer in a prospective cohort study: the Netherlands Cohort Study on Diet and Cancer,” American Journal of Epidemiology, vol. 152, no. 11, pp. 1081–1092, 2000.
[4]
A. T. Dinkova-Kostova and R. V. Kostov, “Glucosinolates and isothiocyanates in health and disease,” Trends in Molecular Medicine, vol. 18, pp. 337–347, 2012.
[5]
A. Melchini, C. Costa, M. Traka et al., “Erucin, a new promising cancer chemopreventive agent from rocket salads, shows anti-proliferative activity on human lung carcinoma A549 cells,” Food and Chemical Toxicology, vol. 47, no. 7, pp. 1430–1436, 2009.
[6]
C. Bonnesen, I. M. Eggleston, and J. D. Hayes, “Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines,” Cancer Research, vol. 61, no. 16, pp. 6120–6130, 2001.
[7]
R. Munday and C. M. Munday, “Induction of phase II detoxification enzymes in rats by plant-derived isothiocyanates: comparison of allyl isothiocyanate with sulforaphane and related compounds,” Journal of Agricultural and Food Chemistry, vol. 52, no. 7, pp. 1867–1871, 2004.
[8]
A. F. A. Razis, M. Bagatta, G. R. De Nicola, R. Iori, and C. Ioannides, “Intact glucosinolates modulate hepatic cytochrome P450 and phase II conjugation activities and may contribute directly to the chemopreventive activity of cruciferous vegetables,” Toxicology, vol. 277, no. 1–3, pp. 74–85, 2010.
[9]
S. L. Navarro, F. Li, and J. W. Lampe, “Mechanisms of action of isothiocyanates in cancer chemoprevention: an update,” Food and Function, vol. 2, no. 10, pp. 579–587, 2011.
[10]
R. Verkerk, M. Schreiner, A. Krumbein et al., “Glucosinolates in Brassica vegetables: the influence of the food supply chain on intake, bioavailability and human health,” Molecular Nutrition and Food Research, vol. 53, no. 2, pp. 219–265, 2009.
[11]
J. D. Hayes, M. O. Kelleher, and I. M. Eggleston, “The cancer chemopreventive actions of phytochemicals derived from glucosinolates,” European Journal of Nutrition, vol. 47, no. 2, pp. 73–88, 2008.
[12]
N. Juge, R. F. Mithen, and M. Traka, “Molecular basis for chemoprevention by sulforaphane: a comprehensive review,” Cellular and Molecular Life Sciences, vol. 64, no. 9, pp. 1105–1127, 2007.
[13]
L. G. Wang, A. Beklemisheva, X. M. Liu, A. C. Ferrari, J. Feng, and J. W. Chiao, “Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer,” Molecular Carcinogenesis, vol. 46, no. 1, pp. 24–31, 2007.
[14]
A. Gong, M. He, D. K. Vanaja, P. Yin, R. Jeffrey Karnes, and C. Y. F. Young, “Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells,” Molecular Nutrition and Food Research, vol. 53, no. 7, pp. 878–886, 2009.
[15]
X.-H. Wang, B. E. Cavell, S. S. S. Alwi, and G. Packham, “Inhibition of hypoxia inducible factor by phenethyl isothiocyanate,” Biochemical Pharmacology, vol. 78, no. 3, pp. 261–272, 2009.
[16]
J.-K. Moon, J.-R. Kim, Y.-J. Ahn, and T. Shibamoto, “Analysis and anti- helicobacter activity of sulforaphane and related compounds present in Broccoli (Brassica oleracea L.) sprouts,” Journal of Agricultural and Food Chemistry, vol. 58, no. 11, pp. 6672–6677, 2010.
[17]
J. J. Michnovicz and H. L. Bradlow, “Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol,” Nutrition and Cancer, vol. 16, no. 1, pp. 59–66, 1991.
[18]
A. Yanaka, J. W. Fahey, A. Fukumoto et al., “Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans,” Cancer Prevention Research, vol. 2, no. 4, pp. 353–360, 2009.
[19]
S. C. Gupta, J. H. Kim, S. Prasad, and B. B. Aggarwal, “Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals,” Cancer and Metastasis Reviews, vol. 29, no. 3, pp. 405–434, 2010.
[20]
Y.-J. Surh and H.-K. Na, “NF-κB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals,” Genes and Nutrition, vol. 2, no. 4, pp. 313–317, 2008.
[21]
S. C. Gupta, C. Sundaram, S. Reuter, and B. B. Aggarwal, “Inhibiting NF-κB activation by small molecules as a therapeutic strategy,” Biochimica et Biophysica Acta, vol. 1799, no. 10-12, pp. 775–787, 2010.
[22]
L. F. Chen and W. C. Greene, “Shaping the nuclear action of NF-κB,” Nature Reviews Molecular Cell Biology, vol. 5, pp. 392–401, 2004.
[23]
F. Chen, V. Castranova, and X. Shi, “New insights into the role of nuclear factor-κB in cell growth regulation,” American Journal of Pathology, vol. 159, no. 2, pp. 387–397, 2001.
[24]
E. Shaulian and M. Karin, “AP-1 in cell proliferation and survival,” Oncogene, vol. 20, no. 19, pp. 2390–2400, 2001.
[25]
E. Shaulian and M. Karin, “AP-1 as a regulator of cell life and death,” Nature Cell Biology, vol. 4, no. 5, pp. E131–E136, 2002.
[26]
E. Heiss, C. Herhaus, K. Klimo, H. Bartsch, and C. Gerh？user, “Nuclear factor κB is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms,” The Journal of Biological Chemistry, vol. 276, no. 34, pp. 32008–32015, 2001.
[27]
W.-S. Jeong, I.-W. Kim, R. Hu, and A.-N. T. Kong, “Modulatory properties of various natural chemopreventive agents on the activation of NF-κB signaling pathway,” Pharmaceutical Research, vol. 21, no. 4, pp. 661–670, 2004.
[28]
K. J. Woo and T. K. Kwon, “Sulforaphane suppresses lipopolysaccharide-induced cyclooxygenase-2 (COX-2) expression through the modulation of multiple targets in COX-2 gene promoter,” International Immunopharmacology, vol. 7, no. 13, pp. 1776–1783, 2007.
[29]
Y.-H. Chen, H.-J. Dai, and H.-P. Chang, “Suppression of inducible nitric oxide production by indole and isothiocyanate derivatives from Brassica plants in stimulated macrophages,” Planta Medica, vol. 69, no. 8, pp. 696–700, 2003.
[30]
A. Prawan, C. L. L. Saw, T. O. Khor et al., “Anti-NF-κB and anti-inflammatory activities of synthetic isothiocyanates: effect of chemical structures and cellular signaling,” Chemico-Biological Interactions, vol. 179, no. 2-3, pp. 202–211, 2009.
[31]
P. Rose, K. W. Yen, N. O. Choon, and M. Whiteman, “β-Phenylethyl and 8-methylsulphinyloctyl isothiocyanates, constituents of watercress, suppress LPS induced production of nitric oxide and prostaglandin E2 in RAW 264.7 macrophages,” Nitric Oxide, vol. 12, no. 4, pp. 237–243, 2005.
[32]
Y. H. Kim, H.-S. Kwon, D. H. Kim et al., “3,3′-diindolylmethane attenuates colonic inflammation and tumorigenesis in mice,” Inflammatory Bowel Diseases, vol. 15, no. 8, pp. 1164–1173, 2009.
[33]
A. E. Wagner, O. Will, C. Sturm, S. Lipinski, et al., “DSS-induced acute colitis in C57BL/6 mice is mitigated by sulforaphane pre-treatment,” The Journal of Nutritional Biochemistry, vol. 25, pp. 2085–2091, 2013.
[34]
Y.-S. Keum, W.-S. Jeong, and A. N. Tony Kong, “Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms,” Mutation Research, vol. 555, no. 1-2, pp. 191–202, 2004.
[35]
Y. Shan, R. Zhao, W. Geng et al., “Protective effect of sulforaphane on human vascular endothelial cells against lipopolysaccharide-induced inflammatory damage,” Cardiovascular Toxicology, vol. 10, no. 2, pp. 139–145, 2010.
[36]
C. Xu, G. Shen, C. Chen, C. Gélinas, and A.-N. T. Kong, “Suppression of NF-κB and NF-κB-regulated gene expression by sulforaphane and PEITC through IκBα, IKK pathway in human prostate cancer PC-3 cells,” Oncogene, vol. 24, no. 28, pp. 4486–4495, 2005.
[37]
M.-D. Yang, K.-C. Lai, T.-Y. Lai et al., “Phenethyl isothiocyanate inhibits migration and invasion of human gastric cancer AGS cells through suppressing MAPK and NF-κB signal pathways,” Anticancer Research, vol. 30, no. 6, pp. 2135–2143, 2010.
[38]
P. Anand, A. B. Kunnumakkara, K. B. Harikumar, S. A. Kwang, V. Badmaev, and B. B. Aggarwal, “Modification of cysteine residue in p65 subunit of nuclear factor-κB (NF-κB) by picroliv suppresses NF-κB-regulated gene products and potentiates apoptosis,” Cancer Research, vol. 68, no. 21, pp. 8861–8870, 2008.
[39]
E. Heiss and C. Gerh？user, “Time-dependent modulation of thioredoxin reductase activity might contribute to sulforaphane-mediated inhibition of NF-κB binding to DNA,” Antioxidants and Redox Signaling, vol. 7, no. 11-12, pp. 1601–1611, 2005.
[40]
Y.-J. Surh, “Cancer chemoprevention with dietary phytochemicals,” Nature Reviews Cancer, vol. 3, no. 10, pp. 768–780, 2003.
[41]
Y.-J. Surh, J. K. Kundu, H.-K. Na, and J.-S. Lee, “Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals,” Journal of Nutrition, vol. 135, no. 12, pp. 2993S–3001S, 2005.
[42]
T. O. Khor, M.-T. Huang, K. H. Kwon, J. Y. Chan, B. S. Reddy, and A.-N. Kong, “Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis,” Cancer Research, vol. 66, no. 24, pp. 11580–11584, 2006.
[43]
E. Balogun, M. Hoque, P. Gong et al., “Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element,” Biochemical Journal, vol. 371, no. 3, pp. 887–895, 2003.
[44]
R. K. Thimmulappa, H. Lee, T. Rangasamy et al., “Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis,” The Journal of Clinical Investigation, vol. 116, no. 4, pp. 984–995, 2006.
[45]
A. E. Wagner, I. Ernst, R. Iori, C. Desel, and G. Rimbach, “Sulforaphane but not ascorbigen, indole-3-carbinole and ascorbic acid activates the transcription factor Nrf2 and induces phase-2 and antioxidant enzymes in human keratinocytes in culture,” Experimental Dermatology, vol. 19, no. 2, pp. 137–144, 2010.
[46]
C. Xu, M.-T. Huang, G. Shen et al., “Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2,” Cancer Research, vol. 66, no. 16, pp. 8293–8296, 2006.
[47]
Y.-S. Keum, “Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications,” Annals of the New York Academy of Sciences, vol. 1229, no. 1, pp. 184–189, 2011.
[48]
C. L. Saw, M.-T. Huang, Y. Liu, T. O. Khor, A. H. Conney, and A.-N. Kong, “Impact of Nrf2 on UVB-induced skin inflammation/photoprotection and photoprotective effect of sulforaphane,” Molecular Carcinogenesis, vol. 50, no. 6, pp. 479–486, 2011.
[49]
I. M. A. Ernst, A. E. Wagner, C. Schuemann et al., “Allyl-, butyl- and phenylethyl-isothiocyanate activate Nrf2 in cultured fibroblasts,” Pharmacological Research, vol. 63, no. 3, pp. 233–240, 2011.
[50]
C. L.-L. Saw, M. Cintrón, T.-Y. Wu et al., “Pharmacodynamics of dietary phytochemical indoles I3C and DIM: induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates,” Biopharmaceutics and Drug Disposition, vol. 32, no. 5, pp. 289–300, 2011.
[51]
G.-H. Liu, J. Qu, and X. Shen, “NF-κB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK,” Biochimica et Biophysica Acta, vol. 1783, no. 5, pp. 713–727, 2008.
[52]
H. Yang, N. Magilnick, X. Ou, and S. C. Lu, “Tumour necrosis factor α induces co-ordinated activation of rat GSH synthetic enzymes via nuclear factor κB and activator protein-1,” Biochemical Journal, vol. 391, no. 2, pp. 399–408, 2005.
[53]
G. Egger, G. Liang, A. Aparicio, and P. A. Jones, “Epigenetics in human disease and prospects for epigenetic therapy,” Nature, vol. 429, no. 6990, pp. 457–463, 2004.
[54]
J. Winter, S. Jung, S. Keller, R. I. Gregory, and S. Diederichs, “Many roads to maturity: microRNA biogenesis pathways and their regulation,” Nature Cell Biology, vol. 11, no. 3, pp. 228–234, 2009.
[55]
C. B. Yoo and P. A. Jones, “Epigenetic therapy of cancer: past, present and future,” Nature Reviews Drug Discovery, vol. 5, no. 1, pp. 37–50, 2006.
[56]
C. Gerhauser, “Cancer chemoprevention and nutriepigenetics: state of the art and future challenges,” Topics in Current Chemistry, vol. 329, pp. 73–132, 2013.
[57]
T. Esatbeyoglu, P. Huebbe, I. M. Ernst, D. Chin, et al., “Curcumin—from molecule to biological function,” Angewandte Chemie International Edition, vol. 51, no. 22, pp. 5308–5332, 2012.
[58]
R. Kanwal and S. Gupta, “Epigenetics and cancer,” Journal of Applied Physiology, vol. 109, no. 2, pp. 598–605, 2010.
[59]
S. Reuter, S. C. Gupta, B. Park, A. Goel, and B. B. Aggarwal, “Epigenetic changes induced by curcumin and other natural compounds,” Genes and Nutrition, vol. 6, no. 2, pp. 93–108, 2011.
[60]
Y. Li, Y. I. Hassan, H. Moriyama, and J. Zempleni, “Holocarboxylase synthetase interacts physically with euchromatic histone-lysine N, linking histone biotinylation with methylation events,” The Journal of Nutritional Biochemistry, vol. 24, no. 8, pp. 1446–1452, 2013.
[61]
J. Xue, S. S. Wijeratne, and J. Zempleni, “Holocarboxylase synthetase synergizes with methyl CpG binding protein 2 and DNA methyltransferase 1 in the transcriptional repression of long-terminal repeats,” Epigenetics, vol. 8, pp. 504–511, 2013.
[62]
K. Zhang and S. Y. R. Dent, “Histone modifying enzymes and cancer: going beyond histones,” Journal of Cellular Biochemistry, vol. 96, no. 6, pp. 1137–1148, 2005.
[63]
S. Saini, S. Arora, S. Majid et al., “Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer,” Cancer Prevention Research, vol. 4, no. 10, pp. 1698–1709, 2011.
[64]
S. Spiegel, S. Milstien, and S. Grant, “Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy,” Oncogene, vol. 31, no. 5, pp. 537–551, 2012.
[65]
W. S. Xu, R. B. Parmigiani, and P. A. Marks, “Histone deacetylase inhibitors: molecular mechanisms of action,” Oncogene, vol. 26, no. 37, pp. 5541–5552, 2007.
[66]
P. Rajendran, D. E. Williams, E. Ho, and R. H. Dashwood, “Metabolism as a key to histone deacetylase inhibition,” Critical Reviews in Biochemistry and Molecular Biology, vol. 46, no. 3, pp. 181–199, 2011.
[67]
P. Rajendran, A. I. Kidane, T. W. Yu, W. M. Dashwood, et al., “HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates,” Epigenetics, vol. 8, no. 6, pp. 612–623, 2013.
[68]
P. Rajendran, B. Delage, W. M. Dashwood et al., “Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly,” Molecular Cancer, vol. 10, article 68, 2011.
[69]
J. D. Clarke, A. Hsu, Z. Yu, R. H. Dashwood, and E. Ho, “Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells,” Molecular Nutrition and Food Research, vol. 55, no. 7, pp. 999–1009, 2011.
[70]
M. C. Myzak, K. Hardin, R. Wang, R. H. Dashwood, and E. Ho, “Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells,” Carcinogenesis, vol. 27, no. 4, pp. 811–819, 2006.
[71]
A. Pledgie-Tracy, M. D. Sobolewski, and N. E. Davidson, “Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines,” Molecular Cancer Therapeutics, vol. 6, no. 3, pp. 1013–1021, 2007.
[72]
M. C. Myzak, W. M. Dashwood, G. A. Orner, E. Ho, and R. H. Dashwood, “Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice,” FASEB Journal, vol. 20, no. 3, pp. 506–508, 2006.
[73]
M. C. Myzak, P. Tong, W.-M. Dashwood, R. H. Dashwood, and E. Ho, “Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects,” Experimental Biology and Medicine, vol. 232, no. 2, pp. 227–234, 2007.
[74]
L. G. Wang, X. M. Liu, Y. Fang et al., “De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc,” International Journal of Oncology, vol. 33, no. 2, pp. 375–380, 2008.
[75]
A. A. Beklemisheva, Y. Fang, J. Feng, X. Ma, W. Dai, and J. W. Chiao, “Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells,” Anticancer Research, vol. 26, no. 2 A, pp. 1225–1230, 2006.
[76]
Q. Lu, X. Lin, J. Feng et al., “Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways,” Journal of hematology & oncology, vol. 1, p. 6, 2008.
[77]
X. Ma, Y. Fang, A. Beklemisheva et al., “Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells,” International Journal of Oncology, vol. 28, no. 5, pp. 1287–1293, 2006.
[78]
S. Batra, R. P. Sahu, P. K. Kandala, and S. K. Srivastava, “Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-κB turnoff in human pancreatic carcinoma cells,” Molecular Cancer Therapeutics, vol. 9, no. 6, pp. 1596–1608, 2010.
[79]
L. M. Beaver, T. W. Yu, E. I. Sokolowski, D. E. Williams, et al., “3, 3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells,” Toxicol Appl Pharmacol, vol. 263, no. 3, pp. 345–351, 2012.
[80]
R. H. Dashwood and E. Ho, “Dietary histone deacetylase inhibitors: from cells to mice to man,” Seminars in Cancer Biology, vol. 17, no. 5, pp. 363–369, 2007.
[81]
M. Esteller, “Cancer epigenomics: DNA methylomes and histone-modification maps,” Nature Reviews Genetics, vol. 8, no. 4, pp. 286–298, 2007.
[82]
A. Hermann, H. Gowher, and A. Jeltsch, “Biochemistry and biology of mammalian DNA methyltransferases,” Cellular and Molecular Life Sciences, vol. 61, no. 19-20, pp. 2571–2587, 2004.
[83]
G. H. Kang, H. J. Lee, K. S. Hwang, S. Lee, J.-H. Kim, and J.-S. Kim, “Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation,” American Journal of Pathology, vol. 163, no. 4, pp. 1551–1556, 2003.
[84]
S. M. Meeran, S. N. Patel, and T. O. Tollefsbol, “Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines,” PLoS ONE, vol. 5, no. 7, Article ID e11457, 2010.
[85]
L. N. Barrera, I. T. Johnson, Y. Bao, A. Cassidy, et al., “Colorectal cancer cells Caco-2 and HCT116 resist epigenetic effects of isothiocyanates and selenium in vitro,” European Journal of Nutrition, vol. 52, no. 4, pp. 1327–1341, 2013.
[86]
A. Hsu, C. P. Wong, Z. Yu, D. E. Williams, et al., “Promoter de-methylation of cyclin D2 by sulforaphane in prostate cancer cells,” Clin Epigenetics, vol. 3, no. 1, 2011.
[87]
H. Fan, R. Zhang, D. Tesfaye, E. Tholen, et al., “Sulforaphane causes a major epigenetic repression of myostatin in porcine satellite cells,” Epigenetics, vol. 7, pp. 1379–1390, 2012.
[88]
S. Jiang, X. Ma, Y. Huang, Y. Xu, R. Zheng, and J.-W. Chiao, “Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin,” Journal of Hematology and Oncology, vol. 3, article 48, 2010.
[89]
R. M. O'Connell, K. D. Taganov, M. P. Boldin, G. Cheng, and D. Baltimore, “MicroRNA-155 is induced during the macrophage inflammatory response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 5, pp. 1604–1609, 2007.
[90]
K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore, “NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12481–12486, 2006.
[91]
M. A. Valencia-Sanchez, J. Liu, G. J. Hannon, and R. Parker, “Control of translation and mRNA degradation by miRNAs and siRNAs,” Genes and Development, vol. 20, no. 5, pp. 515–524, 2006.
[92]
D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.
[93]
L. He and G. J. Hannon, “MicroRNAs: small RNAs with a big role in gene regulation,” Nature Reviews Genetics, vol. 5, no. 7, pp. 522–531, 2004.
[94]
C. Boesch-Saadatmandi, A. Loboda, A. E. Wagner et al., “Effect of quercetin and its metabolites isorhamnetin and quercetin-3-glucuronide on inflammatory gene expression: role of miR-155,” Journal of Nutritional Biochemistry, vol. 22, no. 3, pp. 293–299, 2011.
[95]
B. C. Bernardo, F. J. Charchar, R. C. Y. Lin, and J. R. McMullen, “A MicroRNA guide for clinicians and basic scientists: background and experimental techniques,” Heart Lung and Circulation, vol. 21, no. 3, pp. 131–142, 2012.
[96]
O. Slaby, M. Sachlova, V. Brezkova, R. Hezova, et al., “Identification of microRNAs regulated by isothiocyanates and association of polymorphisms inside their target sites with risk of sporadic colorectal cancer,” Nutrition and Cancer, vol. 65, no. 2, pp. 247–254, 2013.
[97]
J. Xiao, A.-Y. Gong, A. N. Eischeid et al., “miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein,” Prostate, vol. 72, pp. 1514–1522, 2012.
[98]
A. Basu, H. Alder, A. Khiyami, P. Leahy, C. M. Croce, and S. Haldar, “MicroRNA-375 and microRNA-221: potential noncoding RNAs associated with antiproliferative activity of Benzyl isothiocyanate in pancreatic cancer,” Genes and Cancer, vol. 2, no. 2, pp. 108–119, 2011.
[99]
A. E. Wagner, C. Boesch-Saadatmandi, J. Dose, G. Schultheiss, et al., “Anti-inflammatory potential of allyl-isothiocyanate—role of Nrf2, NF-κB and microRNA-155,” J Cell Mol Med, vol. 16, pp. 836–843, 2012.
[100]
A. Izzotti, P. Larghero, C. Cartiglia et al., “Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung,” Carcinogenesis, vol. 31, no. 5, pp. 894–901, 2010.
[101]
A. Izzotti, G. A. Calin, V. E. Steele et al., “Chemoprevention of cigarette smoke-induced alterations of microRNA expression in rat lungs,” Cancer Prevention Research, vol. 3, no. 1, pp. 62–72, 2010.
[102]
Y. Li, D. Kong, Z. Wang, and F. H. Sarkar, “Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research,” Pharmaceutical Research, vol. 27, no. 6, pp. 1027–1041, 2010.
[103]
Y. Li, T. G. VandenBoom II, Z. Wang et al., “miR-146a suppresses invasion of pancreatic cancer cells,” Cancer Research, vol. 70, no. 4, pp. 1486–1495, 2010.
[104]
M. Yang, Y. Yao, G. Eades, Y. Zhang, and Q. Zhou, “MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism,” Breast Cancer Research and Treatment, vol. 129, no. 3, pp. 983–991, 2011.
[105]
M. Narasimhan, D. Patel, D. Vedpathak, M. Rathinam, et al., “Identification of novel microRNAs in post-transcriptional control of Nrf2 expression and redox homeostasis in neuronal, SH-SY5Y cells,” PLoS ONE, vol. 7, 2012.
[106]
C. Sangokoya, M. J. Telen, and J.-T. Chi, “microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease,” Blood, vol. 116, no. 20, pp. 4338–4348, 2010.
[107]
B. Singh, A. M. Ronghe, A. Chatterjee, N. K. Bhat, et al., “MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis,” Carcinogenesis, vol. 34, pp. 1165–1172, 2013.
[108]
A. Stachurska, M. Ciesla, M. Kozakowska, S. Wolffram, et al., “Cross-talk between microRNAs, nuclear factor E2-related factor 2, and heme oxygenase-1 in ochratoxin A-induced toxic effects in renal proximal tubular epithelial cells,” Molecular Nutrition & Food Research, vol. 57, no. 3, pp. 504–515, 2013.
[109]
G. Eades, M. Yang, Y. Yao, Y. Zhang, and Q. Zhou, “miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells,” The Journal of Biological Chemistry, vol. 286, no. 47, pp. 40725–40733, 2011.
[110]
A. Petrelli, A. Perra, D. Cora, P. Sulas, et al., “MiRNA/gene profiling unveils early molecular changes and NRF2 activation in a rat model recapitulating human HCC,” Hepatology, vol. 2013, 2013.
[111]
M. T. van Jaarsveld, J. Helleman, A. W. Boersma, P. F. van Kuijk, et al., “miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells,” Oncogene, vol. 32, pp. 4284–4293, 2013.
[112]
M. Yamamoto, A. Singh, F. Sava, M. Pui, et al., “MicroRNA expression in response to controlled exposure to diesel exhaust: attenuation by the antioxidant N in a randomized crossover study,” Environ Health Perspect, vol. 121, pp. 670–675, 2013.
[113]
A. Singh, C. Happel, S. K. Manna, G. Acquaah-Mensah, et al., “Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis,” The Journal of Clinical Investigation, vol. 123, pp. 2921–2934, 2013.
[114]
J. W. Fahey, A. T. Zalcmann, and P. Talalay, “The chemical diversity and distribution of glucosinolates and isothiocyanates among plants,” Phytochemistry, vol. 56, no. 1, pp. 5–51, 2001.
[115]
W.-S. Jeong, M. Jun, and A.-N. T. Kong, “Nrf2: a potential molecular target for cancer chemoprevention by natural compounds,” Antioxidants and Redox Signaling, vol. 8, no. 1-2, pp. 99–106, 2006.
[116]
T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007.
[117]
I. Rahman, J. Marwick, and P. Kirkham, “Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-κB and pro-inflammatory gene expression,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1255–1267, 2004.
[118]
M. Karin and F. R. Greten, “NF-κB: linking inflammation and immunity to cancer development and progression,” Nature Reviews Immunology, vol. 5, no. 10, pp. 749–759, 2005.
